Related Experiment Video
Updated: May 8, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Lipid-lowing pharmacogenomics in Chinese patients
1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR.
Abstract:
Pharmacogenomic studies on statins ranging from the candidate gene approach to the genome-wide studies in western populations have provided evidence that genetic variations play a limited role in determining statin responses. However, there are ethnic difference in the pharmacokinetics and safety of statins and due to the different frequencies of polymorphisms and different linkage disequilibrium patterns among the ethnic groups, the genetic markers identified in genome-wide association study platforms or in candidate gene studies in one population cannot always be generalized to other populations. This review provides an overview on the pharmacogenomics of statins in Chinese population.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes